Menu
Back to Journals » Drug Design, Development and Therapy » Volume 6 » default
Drug Design, Development and Therapy
ISSN: 1177-8881
- View all (4023)
- Volume 17, 2023 (267)
- Volume 16, 2022 (316)
- Volume 15, 2021 (399)
- Volume 14, 2020 (477)
- Volume 13, 2019 (387)
- Volume 12, 2018 (382)
- Volume 11, 2017 (330)
- Volume 10, 2016 (374)
- Volume 9, 2015 (543)
- Volume 8, 2014 (231)
- Volume 7, 2013 (143)
- Volume 6, 2012 (42)
- Volume 5, 2011 (40)
- Volume 4, 2010 (35)
- Volume 3, 2009 (27)
- Volume 2, 2008 (29)
- Volume 1, 2007 (1)
Archive: Volume 6, 2012
Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study
Smith WB, Mannaert E, Verhaeghe T, Kerstens R, Vandeplassche L, Van de Velde V
Drug Design, Development and Therapy 2012, 6:407-415
Published Date: 18 December 2012
Dabrafenib and its potential for the treatment of metastatic melanoma
Menzies AM, Long GV, Murali R
Drug Design, Development and Therapy 2012, 6:391-405
Published Date: 11 December 2012
Chronic eosinophilic pneumonia due to radiographic contrast administration: an orphan disease?
Hohenforst-Schmidt W, Riedel A, Zarogoulidis P, Franke C, Gschwendtner A, Huang H, Machairiotis N, Dramba V, Zarogoulidis K, Brachmann J
Drug Design, Development and Therapy 2012, 6:385-389
Published Date: 10 December 2012
Update on taxane development: new analogs and new formulations
Yared JA, Tkaczuk KH
Drug Design, Development and Therapy 2012, 6:371-384
Published Date: 11 December 2012
Pretreatment data is highly predictive of liver chemistry signals in clinical trials
Cai Z, Bresell A, Steinberg MH, Silberg DG, Furlong ST
Drug Design, Development and Therapy 2012, 6:359-369
Published Date: 27 November 2012
Potential role of rivaroxaban in patients with acute coronary syndrome
Fitchett DH
Drug Design, Development and Therapy 2012, 6:349-357
Published Date: 22 November 2012
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
Yang X, Chen Y, Hong X, Wu N, Song L,Yuan W, Liu Z
Drug Design, Development and Therapy 2012, 6:341-347
Published Date: 20 November 2012
Potent human uric acid transporter 1 inhibitors: in vitro and in vivo metabolism and pharmacokinetic studies
Wempe MF, Lightner JW, Miller B, Iwen TJ, Rice PJ, Wakui S, Anzai N, Jutabha P, Endou H
Drug Design, Development and Therapy 2012, 6:323-339
Published Date: 8 November 2012
Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors
Xiao HT, Liao Z, Tong RS
Drug Design, Development and Therapy 2012, 6:317-322
Published Date: 1 November 2012
Bioequivalence study of two formulations of bisoprolol fumarate film-coated tablets in healthy subjects
Tjandrawinata RR, Setiawati E, Yunaidi DA, Santoso ID, Setiawati A, Susanto LW
Drug Design, Development and Therapy 2012, 6:311-316
Published Date: 30 October 2012
Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy
Ruiz de Garibay AP, Delgado D, del Pozo-Rodríguez A, Solinís MA, Gascón AR
Drug Design, Development and Therapy 2012, 6:303-310
Published Date: 26 October 2012
Therapy effects of gold nanorods on the CNE-1 nasopharyngeal carcinoma cell line
Shao J, Tang J, Ji J, Zhou W
Drug Design, Development and Therapy 2012, 6:297-301
Published Date: 25 October 2012
Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA
Drug Design, Development and Therapy 2012, 6:289-295
Published Date: 12 October 2012
Efficacy of two novel 2,2’-bifurans to inhibit methicillin-resistant Staphylococcus aureus infection in male mice in comparison to vancomycin
El-Sayed WM, Hussin WA, Ismail MA
Drug Design, Development and Therapy 2012, 6:279-287
Published Date: 12 October 2012
Clinical evaluation of sivelestat for acute lung injury/acute respiratory distress syndrome following surgery for abdominal sepsis
Tsuboko Y, Takeda S, Mii S, Nakazato K, Tanaka K, Uchida E, Sakamoto A
Drug Design, Development and Therapy 2012, 6:273-278
Published Date: 10 October 2012
Current and novel drug therapies for idiopathic pulmonary fibrosis
Adamali HI, Maher TM
Drug Design, Development and Therapy 2012, 6:261-272
Published Date: 26 September 2012
Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib
Goldberg AS, Hegele RA
Drug Design, Development and Therapy 2012, 6:251-259
Published Date: 24 September 2012
Kinase inhibitors: a new class of antirheumatic drugs
Kyttaris VC
Drug Design, Development and Therapy 2012, 6:245-250
Published Date: 21 September 2012
Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
Lambert O, Bandilla D
Drug Design, Development and Therapy 2012, 6:235-244
Published Date: 17 September 2012
Adding thiazide to a rennin-angiotensin blocker regimen to improve left ventricular relaxation in diabetes and nondiabetes patients with hypertension
Takami T, Ito H, Ishii K, Shimada K, Iwakura K, Watanabe H, Fukuda S, Yoshikawa J
Drug Design, Development and Therapy 2012, 6:225-233
Published Date: 12 September 2012
Exploring prospects of novel drugs for tuberculosis
Janssen S, Jayachandran R, Khathi L, Zinsstag J, Grobusch MP, Pieters J
Drug Design, Development and Therapy 2012, 6:217-224
Published Date: 7 September 2012
Natural material adsorbed onto a polymer to enhance immune function
Reinaque AP, França EL, Scherer EF, Côrtes MA, Souto FJ, Honorio-França AC
Drug Design, Development and Therapy 2012, 6:209-216
Published Date: 27 August 2012
Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies
Keir LS, Marks SD, Kim JJ
Drug Design, Development and Therapy 2012, 6:195-208
Published Date: 19 July 2012
The preventive role of transurethral antibiotic delivery in a rat model
Ozok HU, Ekim O, Saltas H, Arikok AT, Babacan O, Sagnak L, Topaloglu H, Ersoy H
Drug Design, Development and Therapy 2012, 6:187-194
Published Date: 17 July 2012
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach
Gasperini C, Ruggieri S
Drug Design, Development and Therapy 2012, 6:175-186
Published Date: 19 July 2012
Emerging options for the management of scorpion stings
Chippaux JP
Drug Design, Development and Therapy 2012, 6:165-173
Published Date: 5 July 2012
Erratum
Todd Levine
Drug Design, Development and Therapy 2012, 6:163-164
Published Date: 21 June 2012
Maintenance of nutritional status in patients with cystic fibrosis: new and emerging therapies
Kalnins D, Wilschanski M
Drug Design, Development and Therapy 2012, 6:151-161
Published Date: 20 June 2012
Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl
McCullough PA, Ali S
Drug Design, Development and Therapy 2012, 6:141-149
Published Date: 14 June 2012
Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series
Levine T
Drug Design, Development and Therapy 2012, 6:133-139
Published Date: 11 June 2012
Novel drug-delivery systems for patients with chronic rhinosinusitis
Albu S
Drug Design, Development and Therapy 2012, 6:125-132
Published Date: 31 May 2012
Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy
Frati F, Incorvaia C, David M, Scurati S, Seta S, Padua G, Cattaneo E, Cavaliere C, Di Rienzo A, Dell'Albani I, Puccinelli P
Drug Design, Development and Therapy 2012, 6:117-123
Published Date: 18 May 2012
Update on the development of lurasidone as a treatment for patients with acute schizophrenia
Yasui-Furukori N
Drug Design, Development and Therapy 2012, 6:107-115
Published Date: 8 May 2012
Imiglucerase in the treatment of Gaucher disease: a history and perspective
Deegan PB, Cox TM
Drug Design, Development and Therapy 2012, 6:81-106
Published Date: 18 April 2012
A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M
Drug Design, Development and Therapy 2012, 6:71-79
Published Date: 19 April 2012
Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted
Lambert O, Bandilla D, Iyer R, Witchey-Lakshmanan L, Palepu N
Drug Design, Development and Therapy 2012, 6:61-70
Published Date: 28 March 2012
Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world
Caldron PH, Gavrilova SI, Kropf S
Drug Design, Development and Therapy 2012, 6:53-60
Published Date: 27 March 2012
Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease
Nordfjeld K, Andreasen H, Thomsen LL
Drug Design, Development and Therapy 2012, 6:43-51
Published Date: 5 March 2012
Solubilization of beclomethasone dipropionate in sterically stabilized phospholipid nanomicelles (SSMs): physicochemical and in vitro evaluations
Sahib MN, Abdulameer SA, Darwis Y, Peh KK, Tan YT
Drug Design, Development and Therapy 2012, 6:29-42
Published Date: 17 February 2012
Inhaled treprostinil: a therapeutic review
Channick RN, Voswinckel R, Rubin LJ
Drug Design, Development and Therapy 2012, 6:19-28
Published Date: 24 January 2012
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
Rehman Y, Rosenberg JE
Drug Design, Development and Therapy 2012, 6:13-18
Published Date: 16 January 2012
Treatment for primary hypothyroidism: current approaches and future possibilities
Chakera AJ, Pearce SHS, Vaidya B
Drug Design, Development and Therapy 2012, 6:1-11
Published Date: 22 December 2011